Statins and pulmonary fibrosis the potential role of NLRP3 inflammasome activation

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 5, 2012, Pages 547-556

  Xu, Jin Fu ^a   Washko, George R ^a   Nakahira, Kiichi ^a   Hatabu, Hiroto ^a   Patel, Avignat S ^a   Fernandez, Isis E ^a   Nishino, Mizuki ^a   Okajima, Yuka ^a   Yamashiro, Tsuneo ^a   Ross, James C ^a   Estépar, Raúl San José ^a   Diaz, Alejandro A ^a,c   Li, Hui Ping ^b   Qu, Jie Ming ^d   Himes, Blanca E ^a   Come, Carolyn E ^a   D'Aco, Katherine ^a   Martinez, Fernando J ^e   Han, MeiLan K ^e   Lynch, David A ^f   Crapo, James D ^f   Morse, Danielle ^a   Ryter, Stefan W ^a   Silverman, Edwin K ^a   Rosas, Ivan O ^a   Choi, Augustine M K ^a   Hunninghake, Gary M ^a   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d FUDAN UNIVERSITY   (China)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Inflammasome; Interstitial lung disease; Mitochondrial reactive oxygen species; Pulmonary fibrosis; Statins

Indexed keywords

BLEOMYCIN; CHOLESTEROL; CRYOPYRIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLAMMASOME; INTERLEUKIN 1BETA CONVERTING ENZYME; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; HYDROPHILICITY; IMMUNE RESPONSE; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG INJURY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOKING; UPREGULATION;

ANIMALS; BLEOMYCIN; CARRIER PROTEINS; CASPASE 1; DRUG SYNERGISM; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IDIOPATHIC PULMONARY FIBROSIS; INFLAMMASOMES; LUNG; MALE; MICE; MICE, INBRED C57BL; PULMONARY FIBROSIS; REGRESSION ANALYSIS; SMOKING;

EID: 84863229387     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201108-1574OC     Document Type: Article

References (50)

1. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313-321. (Pubitemid 27339660)
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009. (Pubitemid 26338729)
5. Morimoto K, Janssen WJ, Fessler MB, McPhillips KA, Borges VM, Bowler RP, Xiao YQ, Kench JA, Henson PM, Vandivier RW. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol 2006;176:7657-7665. (Pubitemid 43849066)
6. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004;109(Suppl. 1):II18-II26. (Pubitemid 38724152)
7. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006;61:729-734. (Pubitemid 44211783)
8. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
9. Tan A, Levrey H, Dahm C, Polunovsky VA, Rubins J, Bitterman PB. Lovastatin induces fibroblast apoptosis in vitro and in vivo. A possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med 1999;159:220-227. (Pubitemid 29036527)
10. Kim JW, Rhee CK, Kim TJ, Kim YH, Lee SH, Yoon HK, Kim SC, Lee SY, Kwon SS, Kim KH, et al. Effect of pravastatin on bleomycininduced acute lung injury and pulmonary fibrosis. Clin Exp Pharmacol Physiol 2010;37:1055-1063.
11. Coward WR, Marei A, Yang A, Vasa-Nicotera MM, Chow SC. Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J Immunol 2006;176:5284-5292.
12. Gasse P, Riteau N, Charron S, Girre S, Fick L, Petrilli V, Tschopp J, Lagente V, Quesniaux VF, Ryffel B, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009;179:903-913.
13. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW, Wynn TA. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 2010;207:535-552.
14. Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA, Aizawa H. Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol 2009;41:661-670.
15. Fernandez AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest 2008;134:824-830.
16. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Ross JC, Estepar RS, Lynch DA, Brehm JM, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011;364:897-906.
17. Lederer DJ, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, van Beek EJ, Austin JH, Jiang R, Lovasi GS, Barr RG. Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)-lung study. Am J Respir Crit Care Med 2009;180:407-414.
18. Washko GR, Lynch DA, Matsuoka S, Ross JC, Umeoka S, Diaz A, Sciurba FC, Hunninghake GM, San Jose Estepar R, Silverman EK, et al. Identification of early interstitial lung disease in smokers from the COPDGene Study. Acad Radiol 2010;17:48-53.
19. Xu J, Nakahira K, Li H, Ryter S, Choi AM. Statins promote NALP3 inflammasome activation through increased mitochondrial ROS generation in macrophages. Presented at the American Thoracic Society International Conference. May, 2011, Denver, Colorado.
20. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, Englert JA, Rabinovitch M, Cernadas M, Kim HP, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011;12:222-230.
21. Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, Ifedigbo E, Xu X, Oury TD, Kaminski N, et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 2006;203:2895-2906. (Pubitemid 46026167)
22. Zhou Z, Song R, Fattman CL, Greenhill S, Alber S, Oury TD, Choi AM, Morse D. Carbon monoxide suppresses bleomycin-induced lung fibrosis. Am J Pathol 2005;166:27-37. (Pubitemid 40051657)
23. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011;475:122.
24. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555. (Pubitemid 47403272)
25. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-313. (Pubitemid 34815352)
26. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria; 2009.
27. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42:963-970. (Pubitemid 34920793)
28. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112:71-105. (Pubitemid 44301483)
29. Ponnuswamy A, Manikandan R, Sabetpour A, Keeping IM, Finnerty JP. Association between ischaemic heart disease and interstitial lung disease: a case-control study. Respir Med 2009;103:503-507.
30. Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008;178:1257-1261.
31. Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S, Schnyder B, Akira S, Quesniaux VF, Lagente V, et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 2007;117:3786-3799. (Pubitemid 350224089)
32. Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly LA, Carter AB, Rothman PB, Flavell RA, Sutterwala FS. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA 2008;105:9035-9040.
33. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008;320:674-677. (Pubitemid 351928351)
34. Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 2006;291:C1208-C1212. (Pubitemid 44878591)
35. Ito M, Adachi T, Pimentel DR, Ido Y, Colucci WS. Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 2004;110:412-418. (Pubitemid 38993850)
36. Bouitbir J, Charles AL, Echaniz-Laguna A, Kindo M, Daussin F, Auwerx J, Piquard F, Geny B, Zoll J. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a mitohormesis mechanism involving reactive oxygen species and PGC-1. Eur Heart J (In press)
37. Ou XM, Feng YL, Wen FQ, Huang XY, Xiao J, Wang K, Wang T. Simvastatin attenuates bleomycin-induced pulmonary fibrosis in mice. Chin Med J (Engl) 2008;121:1821-1829.
38. Pauwels NS, Bracke KR, Dupont LL, Van Pottelberge GR, Provoost S, Berghe TV, Vandenabeele P, Lambrecht BN, Joos GF, Brusselle GG. Role of IL-1{alpha} and the Nlrp3/caspase-1/IL-1{beta} axis in cigarette smoke-induced pulmonary inflammation and COPD. Eur Respir J 2011;38:1019-1028.
39. Doz E, Noulin N, Boichot E, Guenon I, Fick L, Le Bert M, Lagente V, Ryffel B, Schnyder B, Quesniaux VF, et al. Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J Immunol 2008;180:1169-1178.
40. Montero MT, Matilla J, Gomez-Mampaso E, Lasuncion MA. Geranylgeraniol regulates negatively caspase-1 autoprocessing: implication in the Th1 response against Mycobacterium tuberculosis. J Immunol 2004;173:4936-4944. (Pubitemid 39387775)
41. Montero MT, Hernandez O, Suarez Y, Matilla J, Ferruelo AJ, Martinez-Botas J, Gomez-Coronado D, Lasuncion MA. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 2000;153:303-313. (Pubitemid 32120329)
42. Kuijk LM, Mandey SH, Schellens I, Waterham HR, Rijkers GT, Coffer PJ, Frenkel J. Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1. Mol Immunol 2008;45:2158-2165.
43. Massonnet B, Normand S, Moschitz R, Delwail A, Favot L, Garcia M, Bourmeyster N, Cuisset L, Grateau G, Morel F, et al. Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human monocytes. Eur Cytokine Netw 2009;20:112-120.
44. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, van de Veerdonk FL, Ferwerda G, Heinhuis B, Devesa I, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009;113:2324-2335.
45. Lommatzsch M, Cicko S, Muller T, Lucattelli M, Bratke K, Stoll P, Grimm M, Durk T, Zissel G, Ferrari D, et al. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:928-934.
46. Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, Schreiber SL, Golub TR, Mootha VK. Large-scale chemical dissection of mitochondrial function. Nat Biotechnol 2008;26:343-351. (Pubitemid 351355127)
47. Rosas IO, Ren P, Avila NA, Chow CK, Franks TJ, Travis WD, McCoy JP Jr, May RM, Wu HP, Nguyen DM, et al. Early interstitial lung disease in familial pulmonary fibrosis.AmJ Respir CritCareMed 2007;176:698-705. (Pubitemid 47503078)
48. Steele MP, Speer MC, Loyd JE, Brown KK, Herron A, Slifer SH, Burch LH, Wahidi MM, Phillips JA III, Sporn TA, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005;172:1146-1152. (Pubitemid 43066651)
49. Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, MacDonald SD, Travis WD, Stylianou MP, Rosas IO. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008;168:159-166. (Pubitemid 351185882)
50. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-1690. (Pubitemid 37430274)